Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis – a comparison of esomeprazole with other PPIs
Article first published online: 16 AUG 2006
Alimentary Pharmacology & Therapeutics
Volume 24, Issue 5, pages 743–750, September 2006
How to Cite
EDWARDS, S. J., LIND, T. and LUNDELL, L. (2006), Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis – a comparison of esomeprazole with other PPIs. Alimentary Pharmacology & Therapeutics, 24: 743–750. doi: 10.1111/j.1365-2036.2006.03074.x
- Issue published online: 16 AUG 2006
- Article first published online: 16 AUG 2006
- Publication data Submitted 22 June 2006 First decision 28 June 2006 Resubmitted 28 June 2006 Accepted 28 June 2006
No randomized controlled trial has compared all the licensed standard dose proton pump inhibitors in the healing of reflux oesophagitis.
To compare the effectiveness of esomeprazole with licensed standard dose proton pump inhibitors for healing of reflux oesophagitis (i.e. lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg).
Systematic review of CENTRAL, BIOSIS, EMBASE and MEDLINE for randomized controlled trials in patients with reflux oesophagitis. Searching was completed in February 2005. Data on endoscopic healing rates at 4 and 8 weeks were extracted and re-analysed if not analysed by intention-to-treat. Meta-analysis was conducted using a fixed effects model.
Of 133 papers identified in the literature search, six were of sufficient quality to be included in the analysis. No studies were identified comparing rabeprazole with esomeprazole. A meta-analysis of healing rates of esomeprazole 40 mg compared with standard dose proton pump inhibitors gave the following results: at 4 weeks [relative risk (RR) 0.92; 95% CI: 0.90, 0.94; P < 0.00001], and 8 weeks (RR 0.95; 95% CI: 0.94, 0.97; P < 0.00001). Publication bias did not have a significant impact on the results. The results were robust to changes in the inclusion/exclusion criteria and using a random effects model.
Esomeprazole consistently demonstrates higher healing rates when compared with standard dose proton pump inhibitors.